• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, June 23, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

UCLA scientists develop method to more efficiently isolate and identify rare T cells

Bioengineer by Bioengineer
January 12, 2021
in Health
Reading Time: 4 mins read
0
ADVERTISEMENT
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

The advance will help researchers who aim to use these powerful immune cells to treat viruses, cancer and other diseases

IMAGE

Credit: UCLA Broad Stem Cell Research Center

Scientists from the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have developed a technique that will enable researchers to more efficiently isolate and identify rare T cells that are capable of targeting viruses, cancer and other diseases.

The approach could increase scientists’ understanding of how these critical immune cells respond to a wide range of illnesses and advance the development of T cell therapies. This includes immunotherapies that aim to boost the function and quantity of cancer or virus-targeting T cells and therapies intended to regulate the activity of T cells that are overactive in autoimmune diseases such as diabetes and multiple sclerosis.

The study, published today in Proceedings of the National Academy of Sciences, describes how the new method, called CLInt-Seq, combines and improves upon existing techniques to collect and genetically sequence rare T cells.

“T cells are critical for protecting the body against both infections and cancers,” said Pavlo Nesterenko, first author of the new paper and a graduate student in the lab of Dr. Owen Witte. “They’re both the effectors and organizers of the body’s adaptive immune response, which means they can be used as therapeutics and studying their dynamics can shed light on overall immune activity.”

T cells stand out from other immune cells because they are equipped with molecules on their surfaces called T-cell receptors that recognize fragments of foreign proteins called antigens.

Our bodies produce millions and millions of T cells per day and each of these cells has its own distinct set of receptors. Every T-cell receptor is capable of recognizing one specific antigen. One T-cell receptor might recognize an antigen from the virus that causes the common cold while another might recognize an antigen from breast cancer, for example.

When a T cell encounters an antigen its receptor recognizes, it springs to action, producing large numbers of copies of itself and instructing other parts of the immune system to attack cells bearing that antigen.

Researchers around the world are exploring methods to collect T cells with receptors targeting cancer or other illnesses like the SARS-CoV-2 virus from patients, expand those cells in the lab and then return this larger population of targeted T cells to patients to boost their immune response.

“The problem is that in most populations of cells we have access to, whether it be from peripheral blood or samples taken from other parts of the human body, T cells with receptors of interest are found in very low numbers,” said Witte, senior author of the paper and founding director of the UCLA Broad Stem Cell Research Center. “Existing methods for capturing and identifying these T cells are labor-intensive and need improvement.”

Part of the reason this process is inefficient is that when T cells recognize the antigen for which they have the corresponding receptor, they send out signals that prompt other cells nearby to partially activate.

“These so-called bystander cells are excited by the activity around them, but are not really capable of reacting to the antigen that provoked the immune response,” said Witte, who holds the presidential chair in developmental immunology in the department of microbiology, immunology and molecular genetics and is a member of the UCLA Jonsson Comprehensive Cancer Center.

When researchers attempt to isolate T cells with specific receptors using traditional methods, they end up capturing many of these bystander cells. CLInt-Seq alleviates this problem by incorporating a technique that enables researchers to distinguish T cells with receptors of interest from most bystander cells.

Isolating T cells with specific receptors is only the first step. In order for these isolated cells to be useful, they need to be analyzed using droplet-based mRNA sequencing, also known as Drop-seq, which can measure messenger RNA expression in thousands of individual cells at once.

“Once you know the sequence of a T-cell receptor of interest, you can use that information to develop therapies that either make more of that cell in the case of fighting cancer and viruses or introduce regulatory T cells with this receptor sequence to curb an overactive immune response in a given area,” Nesterenko said.

The process of isolating T cells with specific receptors requires that the cells’ contents are fixed in place using chemicals that form bonds between the proteins inside each cell and their surroundings – this technique is known as cross-linking. Unfortunately, cross-linking degrades the T cells’ RNA, which makes Drop-seq analysis very challenging. CLInt-Seq overcomes this hurdle by utilizing a method of cross-linking that is reversible and thus preserves the T cells’ RNA.

“The innovation of this system is that it combines an improved method that identifies T-cell receptors with more specificity with a chemical adaptation that makes this process compatible with droplet-based mRNA sequencing,” Witte said. “This addresses challenges at the heart of finding T-cell receptors for treating cancer and other diseases as well as viral infections – from acute viruses like the virus that causes COVID-19 to chronic viruses like Epstein Barr or herpes.”

Moving forward, the Witte lab is utilizing this technology to address a number of scientific questions, including identifying T-cell receptors that react to the SARS-CoV-2 virus and developing T-cell therapies for prostate cancer.

###

This research was funded by the National Cancer Institute, the Parker Institute for Cancer Immunotherapy, a UCLA Tumor Immunology Training Grant and the UCLA Broad Stem Cell Research Center, including support from the Hal Gaba Director’s Fund for Cancer Stem Cell Rese

Media Contact
Tiare Dunlap
[email protected]

Related Journal Article

http://dx.doi.org/10.1073/pnas.2021190118

Tags: Cell BiologyDevelopmental/Reproductive BiologyImmunology/Allergies/AsthmaMedicine/Health
Share13Tweet8Share2ShareShareShare2

Related Posts

blank

Unlocking Parkinson’s Secrets Through Digital Language Analysis

June 23, 2025
High-Density Brain-Wide Neural Recording in Primates

High-Density Brain-Wide Neural Recording in Primates

June 23, 2025

Closed-Loop Stimulation Halts Epilepsy, Preserves Memory

June 23, 2025

Cholinergic Neurons Control Brain Blood Flow and Fluid

June 23, 2025
Please login to join discussion

POPULAR NEWS

  • Green brake lights in the front could reduce accidents

    Study from TU Graz Reveals Front Brake Lights Could Drastically Diminish Road Accident Rates

    161 shares
    Share 64 Tweet 40
  • Pancreatic Cancer Vaccines Eradicate Disease in Preclinical Studies

    72 shares
    Share 29 Tweet 18
  • New Study Uncovers Unexpected Side Effects of High-Dose Radiation Therapy

    77 shares
    Share 31 Tweet 19
  • How Scientists Unraveled the Mystery Behind the Gigantic Size of Extinct Ground Sloths—and What Led to Their Demise

    65 shares
    Share 26 Tweet 16

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Biocompatible Lossen Rearrangement Achieved in E. coli

New PET Tracer Detects a Wide Range of Invasive Mold Infections Driving Life-Threatening Illnesses in Cancer and Transplant Patients

AI Chatbot Protections Fall Short in Curbing Health Misinformation

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.